Balyasny Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $20M | Buy |
423,170
+344,335
| +437% | +$16.3M | 0.03% | 508 |
|
|
2025
Q1 | $3.08M | Sell |
78,835
-127,733
| -62% | -$4.99M | 0.01% | 1014 |
|
|
2024
Q4 | $11.2M | Sell |
206,568
-153,632
| -43% | -$8.32M | 0.02% | 645 |
|
|
2024
Q3 | $18.2M | Sell |
360,200
-224,063
| -38% | -$11.3M | 0.03% | 485 |
|
|
2024
Q2 | $25.7M | Buy |
584,263
+159,568
| +38% | +$7.02M | 0.05% | 394 |
|
|
2024
Q1 | $21.3M | Sell |
424,695
-173,815
| -29% | -$8.73M | 0.04% | 440 |
|
|
2023
Q4 | $36.1M | Buy |
598,510
+364,260
| +156% | +$22M | 0.07% | 274 |
|
|
2023
Q3 | $13.4M | Buy |
234,250
+164,909
| +238% | +$9.4M | 0.03% | 540 |
|
|
2023
Q2 | $3.54M | Sell |
69,341
-128,366
| -65% | -$6.55M | 0.01% | 866 |
|
|
2023
Q1 | $4.23M | Sell |
197,707
-20,292
| -9% | -$434K | 0.01% | 857 |
|
|
2022
Q4 | $2.29M | Buy |
217,999
+118,125
| +118% | +$1.24M | 0.01% | 1011 |
|
|
2022
Q3 | $795K | Buy |
+99,874
| New | +$795K | ﹤0.01% | 1454 |
|